Back to today’s briefing

Story perspectives

Novo Nordisk Wins Key Legal Battle Against Compounding Pharmacies

4/25/2025

27 6

Summary

Story summary

Novo Nordisk celebrated a major legal triumph as a federal judge rejected attempts by compounding pharmacies to halt FDA actions targeting their unauthorized replicas of Ozempic and Wegovy. This decision comes on the heels of the FDA declaring the semaglutide shortage over, paving the way for strict enforcement against these imitations.

1 of 1

Story summary

Novo Nordisk celebrated a major legal triumph as a federal judge rejected attempts by compounding pharmacies to halt FDA actions targeting their unauthorized replicas of Ozempic and Wegovy. This decision comes on the heels of the FDA declaring the semaglutide shortage over, paving the way for strict enforcement against these imitations.